Skip to Content
Merck
CN

SML2369

Tipelukast

≥98% (HPLC)

Synonym(s):

4-[6-Acetyl-3-[3-[(4-acetyl-3-hydroxy-2-propylphenyl)thio]propoxy]-2-propylphenoxy]butanoic acid, KCA-757, MN-001

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C29H38O7S
CAS Number:
125961-82-2
Molecular Weight:
530.67
UNSPSC Code:
51111800
NACRES:
NA.77
MDL number:
MFCD00886138

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C29H38O7S/c1-5-9-23-25(14-12-22(20(4)31)29(23)36-16-7-11-27(32)33)35-17-8-18-37-26-15-13-21(19(3)30)28(34)24(26)10-6-2/h12-15,34H,5-11,16-18H2,1-4H3,(H,32,33)

SMILES string

CCCC1=C(SCCCOC2=C(CCC)C(OCCCC(O)=O)=C(C(C)=O)C=C2)C=CC(C(C)=O)=C1O

InChI key

KPWYNAGOBXLMSE-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Related Categories

Biochem/physiol Actions

Antifibrotic and anti-inflammatory Leukotriene D4 (LTD4) receptor antagonist and inhibitor of 5-lipoxygenase (5-LO) and phosphodiesterases PDE3 and PDE4.
Tipelukast is a Leukotriene D4 (LTD4) receptor antagonist and an inhibitor of 5-lipoxygenase (5-LO) and also phosphodiesterases PDE3 and PDE4. It has been found to have antifibrotic and anti-inflammatory activity. Tipelukast has been investigated as a possible treatment for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000514865
0000514865
0000202011
0000050948
0000050949

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Nonalcoholic steatohepatitis (NASH) drugs market.
Sorcha Cassidy et al.
Nature reviews. Drug discovery, 15(11), 745-746 (2016-11-04)
Yoshio Sumida et al.
Journal of gastroenterology, 53(3), 362-376 (2017-12-17)
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, and there is no approved pharmacotherapy. The efficacy of vitamin E and pioglitazone has been established in nonalcoholic steatohepatitis (NASH), a progressive form of NAFLD. GLP-1RA and SGLT2

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service